In 2019, Li and colleagues were able to identify a Nb against the HPV16 E7 oncoprotein, Nb2, that, if transfected in HPV16-positive cancer cells and used as intrabody (intracellular antibody), would inhibit the growth of these cells, enlightening the potential and promising application of intrabodies for the therapy of HPV16-associated disease (239). Here, CNTN5 is linked to cancer.